Enanta Pharmaceuticals Announces Advancement of its Zelicapavir Clinical Development Program for the Treatment of Respiratory Syncytial Virus (RSV)
Enanta Pharmaceuticals advanced its lead asset Zelicapavir into a registrational Phase 2b/3 trial for high-risk adults and a Phase 2b pediatric trial following a successful End-of-Phase 2 meeting with the FDA. The adult trial is set to begin in the fourth quarter of 2026 with topline data expected in 2027, while the pediatric study is scheduled to initiate in the third quarter of 2026.
Key figures
- Drug Name
- Zelicapavir
- Phase Of Trial
- Phase 2b, Phase 2b/3
- Adult dose mg
- 800
- Pediatric dose 1
- 5mg/kg (<12 months)
- Pediatric dose 2
- 7.5mg/kg (≥12 months)
- Adult trial start
- 4Q 2026
- Pediatric trial start
- 3Q 2026
- Market opportunity usd
- over $2 billion
- Treatment duration days
- 7
- Topline data expectation
- 2027
- Addressable population us
- greater than 3 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.